ImageneBio (IMA) Debt Ratio (2023 - 2024)
ImageneBio's (IMA) quarterly Debt Ratio came in at 0.54 in Q4 2024, up 10772.08% year-over-year from N/an in Q1 2024, and up 10772.08% quarter-over-quarter from 0.0 in Q4 2023.
Powered by 
Analysis
ImageneBio (IMA) Debt Ratio (2023 - 2024) Analysis & Trends
ImageneBio has disclosed Debt Ratio across 2 years of filings, most recently posting 0.54 for Q4 2024.
- In Q4 2024, Debt Ratio rose 10772.08% year-over-year to 0.54; the TTM figure through Dec 2024 stood at 0.54 (up 10772.08% YoY), while the FY2024 annual figure was 0.54, up 10772.08% from the prior year.
- Debt Ratio came in at 0.54 for Q4 2024 at ImageneBio, up from 0.0 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.54 in Q4 2024 to a low of 0.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 0.66 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.05 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 0.05 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.25 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | ImageneBio | 42.89 Mn | -92.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 0.54 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |